Stock Track | WuXi AppTec Shares Plunge Amid Uncertainty Over Cell Therapy Business

Stock Track

2024-10-08

Shares of WuXi AppTec Co. Ltd. (02359) plummeted by 16.74% on Monday, October 8th, after the company announced that it is assessing options for its cell and gene therapy manufacturing business, WuXi Advanced Therapies (WuXi ATU).

In a filing with the Hong Kong Stock Exchange, WuXi AppTec acknowledged that there is uncertainty as to whether the company will eventually decide to dispose of WuXi ATU or explore other options to retain and continue its operations. The company stated that it is currently assessing the matter and has not formed any decisions regarding the future of WuXi ATU.

The announcement has raised concerns among investors about the potential restructuring or divestment of the WuXi ATU business, which specializes in cell and gene therapy manufacturing. Analysts have expressed mixed views on the impact of this move on WuXi AppTec's overall operations and profitability, as the cell and gene therapy sector is considered a key growth area for the company.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1164994522"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1164994522\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1164994522?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-08 15:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164994522","market":"hk","top_or_hot":-1,"title":"Stock Track | WuXi AppTec Shares Plunge Amid Uncertainty Over Cell Therapy Business","media":"Stock Track","content":"<html><body><p>Shares of WuXi AppTec Co. Ltd. (02359) plummeted by 16.74% on Monday, October 8th, after the company announced that it is assessing options for its cell and gene therapy manufacturing business, WuXi Advanced Therapies (WuXi ATU).</p>\n<p>In a filing with the Hong Kong Stock Exchange, WuXi AppTec acknowledged that there is uncertainty as to whether the company will eventually decide to dispose of WuXi ATU or explore other options to retain and continue its operations. The company stated that it is currently assessing the matter and has not formed any decisions regarding the future of WuXi ATU.</p>\n<p>The announcement has raised concerns among investors about the potential restructuring or divestment of the WuXi ATU business, which specializes in cell and gene therapy manufacturing. Analysts have expressed mixed views on the impact of this move on WuXi AppTec's overall operations and profitability, as the cell and gene therapy sector is considered a key growth area for the company.</p></body></html>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Stock Track | WuXi AppTec Shares Plunge Amid Uncertainty Over Cell Therapy Business</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | WuXi AppTec Shares Plunge Amid Uncertainty Over Cell Therapy Business\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2024-10-08 15:39</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of WuXi AppTec Co. Ltd. (02359) plummeted by 16.74% on Monday, October 8th, after the company announced that it is assessing options for its cell and gene therapy manufacturing business, WuXi Advanced Therapies (WuXi ATU).</p>\n<p>In a filing with the Hong Kong Stock Exchange, WuXi AppTec acknowledged that there is uncertainty as to whether the company will eventually decide to dispose of WuXi ATU or explore other options to retain and continue its operations. The company stated that it is currently assessing the matter and has not formed any decisions regarding the future of WuXi ATU.</p>\n<p>The announcement has raised concerns among investors about the potential restructuring or divestment of the WuXi ATU business, which specializes in cell and gene therapy manufacturing. Analysts have expressed mixed views on the impact of this move on WuXi AppTec's overall operations and profitability, as the cell and gene therapy sector is considered a key growth area for the company.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02359","symbol_name":"藥明康德","start_time":0,"source_url":"","article_id":"1164994522","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164994522","pubTimestamp":1728373150,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of WuXi AppTec Co. Ltd.  plummeted by 16.74% on Monday, October 8th, after the company announced that it is assessing options for its cell and gene therapy manufacturing business, WuXi Advanced Therapies .In a filing with the Hong Kong Stock Exchange, WuXi AppTec acknowledged that there is uncertainty as to whether the company will eventually decide to dispose of WuXi ATU or explore other options to retain and continue its operations. The company stated that it is currently assessing the ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02359":"药明康德"},"translate_title":"股票追踪由于细胞治疗业务的不确定性，药明康德股价暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02359":1},"content_text":"Shares of WuXi AppTec Co. Ltd. (02359) plummeted by 16.74% on Monday, October 8th, after the company announced that it is assessing options for its cell and gene therapy manufacturing business, WuXi Advanced Therapies (WuXi ATU).\nIn a filing with the Hong Kong Stock Exchange, WuXi AppTec acknowledged that there is uncertainty as to whether the company will eventually decide to dispose of WuXi ATU or explore other options to retain and continue its operations. The company stated that it is currently assessing the matter and has not formed any decisions regarding the future of WuXi ATU.\nThe announcement has raised concerns among investors about the potential restructuring or divestment of the WuXi ATU business, which specializes in cell and gene therapy manufacturing. Analysts have expressed mixed views on the impact of this move on WuXi AppTec's overall operations and profitability, as the cell and gene therapy sector is considered a key growth area for the company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}